NCT00896623

SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897

Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,577 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment. PURPOSE: This laboratory study is looking at DNA in tissue samples from women with breast cancer to see if it can predict treatment outcome.

Detailed description

OBJECTIVES: * Determine if polymorphisms resulting in greater activation of cyclophosphamide (CYP2B6, CYP3A4, and CYP3A5) are associated with disease-free survival and treatment toxicities in women with breast cancer. * Determine if polymorphisms resulting in less production of quinone-related oxidative damage of doxorubicin hydrochloride (NQO1, NQO2, NOS2, NOS3, CBR3) are associated with disease-free survival and treatment toxicities in these patients. OUTLINE: This is a multicenter study. Tissue samples archived on clinical trial SWOG-8897 are genotyped for polymorphisms in the CYP3A4, CYP3A5, CYP2B6, NQO1, NQO2, NOS2, NOS3, and CBR3 genes by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Variant alleles are correlated with patient outcome. PROJECTED ACCRUAL: A total of 1,577 patients will be accrued for this study.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
GENETIC	mutation analysis
GENETIC	polymorphism analysis
OTHER	surface-enhanced laser desorption/ionization-time of flight mass spectrometry

Timeline

• Start date: 2006-12-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2009-05-12
• Last updated: 2017-02-17